• 1. Cav2.2 and Cav3.1 calcium channel inhibitors from Valeriana jatamansi Jones
  He-Hai Jiang,Fa-Wu Dong,Jun Zhou,Jiang-Miao Hu,Jian Yang,Yin Nian RSC Adv. 2017 7 45878
• 2. Nano-NiFe2O4 catalyzed microwave assisted one-pot regioselective synthesis of novel 2-alkoxyimidazo[1,2-a]pyridines under aerobic conditions
  Soumen Payra,Arijit Saha,Subhash Banerjee RSC Adv. 2016 6 12402
• 3. Bioactive constituents from toxic seed plants in China
  Jing Qu,Shi-Shan Yu,Dan Du,Ya-Dan Wang RSC Adv. 2013 3 10078

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Iridoids and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Monoterpenoids Iridoids and derivatives
• Iridoids
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Introduction to Valepotriate (CAS No. 18296-44-1)

Valepotriate, a compound with the chemical identifier CAS No. 18296-44-1, is a well-documented substance that has garnered significant attention in the field of pharmaceutical chemistry and pharmacology. This compound, derived from the roots of several plant species, particularly Aconitum napellus (monkshood), has been utilized for centuries in traditional medicine systems across various cultures. Its unique chemical structure and biological properties have made it a subject of extensive research, leading to promising applications in modern medicine.

The molecular composition of Valepotriate encompasses a complex blend of polyacetylenes and other bioactive derivatives. These components contribute to its multifaceted pharmacological effects, which include anti-inflammatory, analgesic, and sedative properties. Recent advancements in analytical chemistry have enabled a more precise characterization of its chemical profile, facilitating better understanding and utilization in therapeutic contexts.

In recent years, the interest in Valepotriate has been further fueled by its potential role in managing chronic pain conditions. Studies have demonstrated that Valepotriate can interact with various neurotransmitter systems, particularly those involving Substance P and bradykinin, which are key mediators of pain perception. This interaction has been explored in clinical trials as a potential alternative or adjunct therapy for patients suffering from neuropathic and arthritic pain.

Moreover, the anti-inflammatory properties of Valepotriate have been a focus of numerous research initiatives. Preclinical studies have indicated that it can modulate inflammatory pathways by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings are particularly relevant in the context of chronic inflammatory diseases, where conventional treatments may have limited efficacy or undesirable side effects.

The sedative effects of Valepotriate have also been subjects of interest, particularly in the context of sleep disorders. Research suggests that Valepotriate can enhance GABAergic neurotransmission, leading to sedative and anxiolytic effects. This mechanism has been investigated as a potential treatment for insomnia and anxiety-related disorders, offering a natural alternative to synthetic sedatives.

One of the most intriguing aspects of Valepotriate is its ability to exhibit tissue-specific effects. Studies have shown that its pharmacological actions can be modulated by factors such as pH levels and enzymatic activity within different biological compartments. This property makes Valepotriate a promising candidate for targeted drug delivery systems, where its bioavailability and therapeutic efficacy can be optimized for specific clinical applications.

The synthesis and purification of Valepotriate have also seen significant advancements in recent years. Modern techniques in organic chemistry have enabled the development of more efficient synthetic routes, allowing for higher yields and purities of the compound. Additionally, high-performance liquid chromatography (HPLC) and mass spectrometry (MS) have become indispensable tools for characterizing its chemical structure and assessing its quality.

The pharmacokinetic profile of Valepotriate has been extensively studied to understand how it is absorbed, distributed, metabolized, and excreted by the body. These studies have revealed that Valepotriate exhibits moderate bioavailability upon oral administration but can be significantly enhanced when used in combination with certain excipients or delivery systems. This knowledge is crucial for developing formulations that maximize therapeutic outcomes while minimizing potential side effects.

In conclusion, Valepotriate (CAS No. 18296-44-1) represents a fascinating compound with diverse pharmacological applications. Its traditional roots combined with modern scientific exploration highlight its potential as a therapeutic agent in various medical conditions. As research continues to uncover new insights into its mechanisms of action and optimal utilization strategies, Valepotriate is poised to play an increasingly important role in contemporary medicine.

• 58523-23-2(valtrate hydrine B3)
• 18296-48-5(10-isovaleroxyvaltrate hydrin)
• 152841-87-7(Butanoic acid, 2-methyl-, 6-(acetyloxy)-4-[(acetyloxy)methyl]-6,7a-dihydrospiro[cyclopenta[c]pyran-7(1H),2'-oxiran]-1-yl ester (9CI))
• 58523-22-1(valtratum acetoxyhydrine)
• 1134138-83-2((1S,7S,8R,9S)-11-acetoxy-10-hydroxy-1,7-diisovaleroxyvaltrate hydrin)
• 27765-23-7(Acevaltrate)
• 22173-55-3(Valepotriat; Valtratum)
• 98302-71-7(N/A)
• 31078-10-1(Butanoic acid,3-methyl-,(1S,2'R,6S,7aS)-6-(acetyloxy)-6,7a-dihydro-4-[(3-methyl-1-oxobutoxy)methyl]spiro[cyclopenta[c]pyran-7(1H),2'-oxiran]-1-ylester)
• 25161-41-5(Acevaltrate)